Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
American Journal of Clinical Oncology
|
October 5, 2001
Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters
K Merati, M said Siadaty, A Andea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2018
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
A Sobrero, A Grothey, T Iveson, et al.
Pancreas
|
January 22, 1998
Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents
R M Mohammad, M C Dugan, A N Mohamed, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 17, 1998
Carbon-11-thymidine and FDG to measure therapy response
A F Shields, D A Mankoff, J M Link, et al.
ESMO Open
|
June 11, 2025
Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy
G Sharma, Y Baca, A F Shields, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2010
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
B F El-Rayes, M Zalupski, T Bekai-Saab, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational status
E B Faber, Y Baca, J Xiu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2021
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
J Y Wang, J Xiu, Y Baca, et al.
Scientific Reports
|
July 2, 2025
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
J Abraham, V Domenyuk, N Perdigones, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
American Journal of Clinical Oncology
|
October 5, 2001
Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters
K Merati, M said Siadaty, A Andea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 14, 2018
The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
A Sobrero, A Grothey, T Iveson, et al.
Pancreas
|
January 22, 1998
Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents
R M Mohammad, M C Dugan, A N Mohamed, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 17, 1998
Carbon-11-thymidine and FDG to measure therapy response
A F Shields, D A Mankoff, J M Link, et al.
ESMO Open
|
June 11, 2025
Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy
G Sharma, Y Baca, A F Shields, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2010
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
B F El-Rayes, M Zalupski, T Bekai-Saab, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational status
E B Faber, Y Baca, J Xiu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2021
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
J Y Wang, J Xiu, Y Baca, et al.
Scientific Reports
|
July 2, 2025
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
J Abraham, V Domenyuk, N Perdigones, et al.
Page
of 5